RIGI and neoplasm: This concept bases on the notion that the provision of high‐dose ligands from an outside source may activate RIG‐I signaling to a greater extent than endogenous ligands in the tumor microenvironment, thus generating high‐level immunity and overcoming immunosuppression and exhaustion.17, 55 In addition, RIG‐I‐expressing (ISG signature‐positive) tumors may be susceptible to the loss of ADAR1,31 which may offer new therapeutic prospects in a subset of patients.